These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8804514)

  • 1. Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine.
    Naik H; Lehr JE; Pienta KJ
    Urology; 1996 Sep; 48(3):508-11. PubMed ID: 8804514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral cyclophosphamide and oral hydroxyurea in the treatment of hormone refractory prostate cancer in rats.
    Naik H; Lehr J; Akhtar A; Pienta K
    Anticancer Res; 1994; 14(6B):2681-4. PubMed ID: 7872701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estramustine-based chemotherapy.
    Hudes G
    Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix.
    Pienta KJ; Lehr JE
    J Urol; 1993 Jun; 149(6):1622-5. PubMed ID: 8501820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
    Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
    Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of prostate cancer growth by estramustine and colchicine.
    Fakih M; Yagoda A; Replogle T; Lehr JE; Pienta KJ
    Prostate; 1995 Jun; 26(6):310-5. PubMed ID: 7784270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer.
    de Souza PL; Cooper MR; Imondi AR; Myers CE
    Clin Cancer Res; 1997 Feb; 3(2):287-94. PubMed ID: 9815685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
    Dimopoulos MA; Panopoulos C; Bamia C; Deliveliotis C; Alivizatos G; Pantazopoulos D; Constantinidis C; Kostakopoulos A; Kastriotis I; Zervas A; Aravantinos G; Dimopoulos C
    Urology; 1997 Nov; 50(5):754-8. PubMed ID: 9372887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
    Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;
    Urol Oncol; 2005; 23(1):1-7. PubMed ID: 15885575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
    Hudes GR; Obasaju C; Chapman A; Gallo J; McAleer C; Greenberg R
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):6-11. PubMed ID: 7597435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism based chemotherapy for prostate cancer.
    Sheridan VR; Tew KD
    Cancer Surv; 1991; 11():239-54. PubMed ID: 1841754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
    Abramjuk C; Lein M; Rothaug W; Krell HW; Loening SA; Jung K
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):275-82. PubMed ID: 16758188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer.
    Naik HR; Lehr JE; Pienta KJ
    Anticancer Res; 1994; 14(6B):2617-9. PubMed ID: 7872690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of estramustine phosphate in the modern management of advanced prostate cancer.
    Ravery V; Fizazi K; Oudard S; Drouet L; Eymard JC; Culine S; Gravis G; Hennequin C; Zerbib M
    BJU Int; 2011 Dec; 108(11):1782-6. PubMed ID: 21756277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination.
    Athanasiadis A; Tsavdaridis D; Rigatos SK; Athanasiadis I; Pergantas N; Stathopoulos GP
    Anticancer Res; 2003; 23(3C):3085-8. PubMed ID: 12926166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.
    Pienta KJ; Redman BG; Bandekar R; Strawderman M; Cease K; Esper PS; Naik H; Smith DC
    Urology; 1997 Sep; 50(3):401-6; discussion 406-7. PubMed ID: 9301705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
    Arah IN; Dixon SC; Horti J; Figg WD
    Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.